CN1430999A - Chinese herbal medicine combination for treating disease of disorder of bowels's function and its product - Google Patents
Chinese herbal medicine combination for treating disease of disorder of bowels's function and its product Download PDFInfo
- Publication number
- CN1430999A CN1430999A CN03112782.7A CN03112782A CN1430999A CN 1430999 A CN1430999 A CN 1430999A CN 03112782 A CN03112782 A CN 03112782A CN 1430999 A CN1430999 A CN 1430999A
- Authority
- CN
- China
- Prior art keywords
- grams
- radix
- gram
- chinese medicine
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 36
- 201000010099 disease Diseases 0.000 title claims description 25
- 241000411851 herbal medicine Species 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 75
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000003826 tablet Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 26
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 20
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims description 16
- 201000007637 bowel dysfunction Diseases 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 12
- 241000756943 Codonopsis Species 0.000 claims description 11
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000829 suppository Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000010271 massa medicata fermentata Substances 0.000 claims description 3
- 241000208340 Araliaceae Species 0.000 claims description 2
- 239000009636 Huang Qi Substances 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract description 47
- 239000007924 injection Substances 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 241000202726 Bupleurum Species 0.000 abstract 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 48
- 206010012735 Diarrhoea Diseases 0.000 description 34
- 230000000694 effects Effects 0.000 description 28
- 230000000968 intestinal effect Effects 0.000 description 28
- 206010010774 Constipation Diseases 0.000 description 23
- 239000002024 ethyl acetate extract Substances 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 21
- 239000002026 chloroform extract Substances 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 206010000087 Abdominal pain upper Diseases 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- 230000013872 defecation Effects 0.000 description 16
- 230000008485 antagonism Effects 0.000 description 15
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 11
- 102000002419 Motilin Human genes 0.000 description 11
- 101800002372 Motilin Proteins 0.000 description 11
- 210000000813 small intestine Anatomy 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 210000004877 mucosa Anatomy 0.000 description 10
- 229910021647 smectite Inorganic materials 0.000 description 10
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 9
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 229960004373 acetylcholine Drugs 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 229910001626 barium chloride Inorganic materials 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000019790 abdominal distention Diseases 0.000 description 7
- 230000036528 appetite Effects 0.000 description 7
- 235000019789 appetite Nutrition 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000008925 spontaneous activity Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 6
- 229960005132 cisapride Drugs 0.000 description 6
- 230000008602 contraction Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 210000001198 duodenum Anatomy 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000003809 water extraction Methods 0.000 description 5
- 229930182837 (R)-adrenaline Natural products 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 229960005139 epinephrine Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 206010000059 abdominal discomfort Diseases 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960001253 domperidone Drugs 0.000 description 3
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- ZTVIKZXZYLEVOL-DGKWVBSXSA-N 2-hydroxy-2-phenylacetic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester Chemical group C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-DGKWVBSXSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 2
- 206010034719 Personality change Diseases 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002908 adrenolytic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010065952 Hyperpathia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028140 Mucous stools Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000035755 Psychosomatic disease Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229960003550 alosetron Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229960004754 astemizole Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 201000000117 functional diarrhea Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000003552 inferior colliculi Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating irritable bowel syndrome (IBS) is prepared from 6 Chinese-medicinal materials including bupleurum root, white peony root, Chuan-xiong rhizome, liquorice root, etc. It may be particles, capsules, tablets, oral liquid injection, etc.
Description
Technical field
The present invention relates to a kind of treatment irritable bowel syndrome (irritable bowel syndrome, IBS) the Chinese medicine compound compositions of disease such as bowel dysfunction such as grade, and the preparation of this Chinese medicine compound compositions.
Background technology
(irritable bowel syndrome is common digestive tract non-organic bowel dysfunction disease IBS) to irritable bowel syndrome, has the chronic clinical characters of outbreak repeatedly.Clinical symptoms show as abdominal discomfort (stomachache, abdominal distention) and intestinal movement unusual, changing (diarrhoea or constipation), stool character unusual (loose stool, Mucous Stool or scleroma are just), defecation frequency as bowl evacuation habit increases and is main performance, and continue to exist or intermittently outbreak, pathologic finding does not have specificity intestinal inflammatory lesion more.At present this disease is still lacked effective Therapeutic Method, so be one of clinical common refractory disease.The IBS prevalence that studies show that American-European countries is about 20%, and annual neopathy rate is 1-2%, and M-F is about 1: 3.The relevant bibliographical information of China, IBS account for gastrointestinal tract special outpatient clinic amount 1/3, account for total crowd's about 15%.Because symptom shows effect repeatedly, long-term existence, to the patient live influence and the inconvenience that brings to work quite obvious, the cost of various inspections and treatment is more considerable.Modern medicine thinks that this disease and nerve, endocrine, immunomodulating system are closely related.Because IBS sickness rate height, external drugmaker falls over each other developing new drug more, but begs till the present, and treatment means is limited, does not still have this sick specific medicament of healing.And medicine is many from lax intestinal smooth muscle, excitement and antagonism neurotransmitter, anxiety, act on limited, usually be at disposing as single symptoms such as diarrhoea or constipation, mainly concentrating on adjusting, antidepressant, dynamics-promoting medicine treatment, calcium-channel antagonists and astringent treatment etc. to the intestinal microecology link.Clinical medicine commonly used mostly is and alleviates some symptom at present, is used for stomachache, the diarrhoea of irritable bowel syndrome as dioctahedral smectite (SEMECDA); The gastrointestinal dynamics-promoting medicine thing of treatment constipation symptom commonly used mainly contains motilium (domperidone, domperidone) is the peripheral nerve dopamine-receptor antagonist, cisapride (cisapride, prepulsid, prepulsid) be a kind of novel gastrointestinal dynamics-promoting medicine, by 5-hydroxy tryptamine (5-HT) not the multiple action of isoacceptor finish the motivator effect.Maleic acid is a kind of new chemical medicine for the treatment of irritable bowel syndrome that Novartis develops for adding thiophene sieve, and its indication is irritable bowel syndrome patient's symptoms such as stomachache, abdominal discomfort and constipation.For adding the cardiac toxicity that thiophene sieve does not have cisapride, littler than cisapride side effect.Shang Shi 5-hydroxytryptamine receptor blocker---alosetron treatment diarrhoea is main irritable bowel syndrome (D-IBS) in recent years.There are some researches show the sex difference of existence.Though above various kinds of drug can be alleviated some symptom of irritable bowel syndrome, in application, exist can't effect a radical cure, shortcomings such as side effect is big, individual variation is obvious, medical expense height.But because the primary disease morbidity relates to spirit, diet, consitution many aspects, in clinical practice, all there are one-sidedness and limitation, still can not satisfy clinical requirement.
IBS has been acknowledged as a kind of psychosomatic disease, is an overdetermined symptom grouping, relates to biology and social mentality's factors such as (comprising intense strain, patient's personality and behavior) in its cause of disease and morbidity.Prove: the pathogenic factor of IBS and Nervous and Mental Factors, the change of intestinal kinetics, eating and drinking without temperance, colon secretion are relevant with absorption function change, alteration of intestinal flora etc.
In the Ancient Times in China medical literature, to early existing a large amount of description and the records of etiology and pathogenesis, symptom and sign and the prophylactic treatment of IBS." organic conception " and the principles such as " determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs " of Chinese medical theory have clear superiority to such treatment of diseases.The basic research of IBS finds that IBS is because nervus centralis and autonomic nervous dysfunction can cause the motion of intestinal tube and secrete due to the dysfunction.IBS patient's intestinal movement is unusual, visceral sensitivity is too high is one of the important pathophysiological basis of IBS morbidity, and morbidity belongs to " having loose bowels " or the models such as " constipation " of the traditional Chinese medical science and raises.Theory of Chinese medical science thinks that primary disease is due to " insufficiency of the spleen excess of the liver ", insufficiency of the spleenly easily is edema with the liver involved insult gram, and the mechanism of qi harmony stagnates, abnormal ascending-descending of QI so that suffer from diarrhoea or constipation.China Chinese medicine medical institutions have adopted Chinese medicine that IBS has been carried out a large amount of exploration and practices.Carry out extensive work at aspects such as the medicine typing of IBS, Therapeutic Principle, the combination of Chinese and Western medicine, obtained good effect.The IBS typing is taked dispersing the stagnated live-QI to relieve the stagnation of QI, pressed down intestinal antidiarrheal; Sweetly lightly hold up spleen, yin nourishing to help fortune; Strengthening the body resistance, warming and invigorating the spleen and stomach; Strong gland damp eliminating, principle is dialectical treats for Qinghua reason intestinal etc., also all achieves tangible results.But report treatment IBS combination physical therapy, acupuncture-moxibustion are arranged, and add, certain curative effect is arranged with abdominal massaging, hot compress or ultrashort wave etc.Adopt Chinese medicine compound and hismanal, vitamin C etc. shared, therapy of combining Chinese and Western medicine IBS curative effect is also very remarkable.
Summary of the invention
The present invention has prescription in mind according to motherland's traditional medicine organic conception, principle with " organic conception " and " determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs ", take all factors into consideration multifactor in this symptom grouping pathogeny comprehensively, and a kind of Chinese medicine compound compositions for the treatment of bowel dysfunction diseases such as irritable bowel syndrome is provided, and the preparation of the preparation of this Chinese medicine compound compositions.The clinical main performance diarrhoea of IBS, constipation, stomachache, alternating diarrhea and constipation; Companion anorexia, asthenia, poor, the agitation of becoming thin, sleep etc.Modern medicine is divided into diarrhea-type, constipation type, alternate type.The relevant applicant of this project from theory of Chinese medical science, thinks that the common and primary reason of IBS is a Nervous and Mental Factors on the basis of clinical treatment and scientific research for many years.Patient is psychentonia, depression, morbidity or increase the weight of when irritated often, belongs to the traditional Chinese medical science " seven emotions " category that causes a disease, pathogenesis be liver lose dredge rush down, perverse and unreasonable manner violates spleen, causes disharmony between the liver and spleen; Or stagnation of QI due to depression of the liver, strongly fragrant fire-transformation of a specified duration, fire consumption body fluid, defeated cloth is lost in Tianjin, can not moisten large intestine, causes dysfunction of the spleen in transportation.The clinical constipation of seeing more, companion's anorexia, abdominal distention, the irritated xerostomia of psychentonia, few disease of waiting of sleeping.Fail to control as the state of an illness, course of disease delay causes weakness of the spleen and stomach, and fortuneization is unable, the biochemical weary source of QI and blood.Then have loose bowels and constipation replaces clinically toward visiting.The course of disease plays i.e. stomachache visible clinically morning to the end, borborygmus, has loose bowels, accompanies coldness of the body with chills, and the soreness of waist is soft, pale tongue with white fur, deep-thready pulse.Therefore, control from liver-spleen disharmony opinion, sum up depressed liver-energy dispersing and QI regulating, spleen invigorating bowel relieving on this basis, yin nourishing helps the Therapeutic Principle of fortune and square substantially through clinical verification.
The basic side of the Chinese medicine composition of above-mentioned treatment bowel dysfunction disease comprises:
Radix Bupleuri 6-15 gram
Radix Paeoniae Alba 5-20 gram
Rhizoma Chuanxiong 3-10 gram
Rhizoma Atractylodis Macrocephalae 6-20 gram
Poria 6-12 gram
Radix Glycyrrhizae 5-20 gram.
Further optimize above scheme: the recommendation consumption of basic prescription is:
Radix Bupleuri 8-12 gram
Radix Paeoniae Alba 9-12 gram
Rhizoma Chuanxiong 5-9 gram
Rhizoma Atractylodis Macrocephalae 9-15 gram
Poria 6-12 gram
Radix Glycyrrhizae 6-15 gram.
Below substantially can be not add other components, directly in clinical use.That is: the composition of said composition is above-mentioned prescription.Simultaneously also can on above-mentioned basic side's basis, increase other compositions, the component that can increase have in the following two class medicines any one or multiple:
1: Radix Codonopsis, Fructus Mume, Fructus Aurantii Immaturus, Radix Saposhnikoviae, Pericarpium Citri Reticulatae, Radix Pseudostellariae, Ramulus Cinnamomi, Rhizoma Cimicifugae, Semen Myristicae, Fructus Schisandrae Chinensis.
2: the Radix Astragali, Radix Ginseng, Radix Puerariae, Ramulus Uncariae Cum Uncis, Radix Angelicae Sinensis, Fructus Jujubae, Rhizoma Zingiberis Recens, Rhizoma Cyperi, the Rhizoma Pinelliae, Radix Curcumae.
For example: when being used for diarrhoea, constipation, stomachache, alternating diarrhea and constipation in various degree, can increase the Radix Aucklandiae 6 grams;
Be used for diarrhoea, stomachache, constipation, alternating diarrhea and constipation, and when significantly becoming thin, sleeping poor symptom in various degree, on basic side basis, increase a kind of in the following scheme combination of components: (1), increase Radix Pseudostellariae 10～18 grams, or, (2), Radix Pseudostellariae 10～18 grams, Pericarpium Citri Reticulatae, each 6 gram of Fructus Aurantii Immaturus; Or (3), Pericarpium Citri Reticulatae 6 grams～9 grams, or (4), Radix Scutellariae 9 grams, Radix Codonopsis 9 grams, Fructus Aurantii Immaturus 6 grams, Rhizoma Cimicifugae 3 grams, or (5), Pericarpium Citri Reticulatae, each 6 gram of Radix Codonopsis.
Be used for abdomen rise, suffer from abdominal pain, with obvious constipation, during diseases such as agitation, can increase: Radix Saposhnikoviae 6 grams, Semen Myristicae 6 grams, Radix Puerariae 9 grams, Fructus Schisandrae Chinensis 6 grams.
Be used for diarrhoea or constipation, and during with diseases such as obviously stomachache, fear of cold, increase a kind of in the following combination of components on basic side basis: (1), Fructus Mume 9 grams, Rhizoma Coptidis 3 grams, Ramulus Cinnamomi 3 grams, Radix Pseudostellariae 6 restrain; Or (2), Semen Myristicae 12 grams, Pericarpium Citri Reticulatae 6 grams, Ramulus Cinnamomi 6 grams, Rhizoma Coptidis 3 grams; Or (3), Ramulus Cinnamomi 9 grams, Pericarpium Citri Reticulatae 6 grams, Radix Curcumae 3 grams.
Being used for diarrhoea, constipation alternately rises, anorexia, when disease such as becoming thin, can increase: Radix Codonopsis 18 grams, Radix Platycodonis 9 grams, Rhizoma Coptidis 3 grams, the Radix Aucklandiae 3 grams, Fructus Crataegi 3 grams, Massa Medicata Fermentata 3 grams, Fructus Aurantii Immaturus 3 grams, Pericarpium Citri Reticulatae 3 grams with tangible abdomen.
The modern formulation of above Chinese medicine composition comprises:
1, the direct or purified suppository that separates granule that the back adds suitable pharmaceutic adjuvant preparation, capsule, tablet, oral liquid, parenteralia (subcutaneous, blood vessel, muscle administration), percutaneous or mucosal preparation, rectally of above extract.
2, above medicine adds granule, capsule, tablet, percutaneous or the mucosal preparation of suitable pharmaceutic adjuvant preparation, the suppository of rectally after crushed.
3, above extract direct or purified separation back and the direct ground product of medicine make up granule, capsule, tablet, percutaneous or the mucosal preparation of back preparation, the suppository of rectally.
The indication scope of this compositions: the gastrointestinal function disorder of people or other general newborn animal.Comprise:
1, the irritable bowel syndrome that brings out by Nervous and Mental Factors (bowel dysfunction).
2, by food or inflammation bring out irritable bowel syndrome (bowel dysfunction)
3, the clinical main performance diarrhoea of IBS, constipation, stomachache, alternating diarrhea and constipation; Companion anorexia, asthenia, poor, the agitation of becoming thin, sleep etc.Modern medicine is divided into diarrhea-type, constipation type.Clinical symptoms is with irregular stomachache, abdominal distention, diarrhoea, and the stool character changes and defecation frequency increases and is main performance.Get rid of other intestinal organic diseases: get rid of thyroid disease, diabetes, nephropathy, cardiovascular diseases, disease of hematopoietic system, ulcerative colitis, clone disease, chronic dysentery, peptic ulcer, chronic hepatitis, anus etc., prevent false positive.Stomachache before generally having following feature (1) is just alleviated after an action of the bowels; Enterokinesia obviously increases when (2) suffering from abdominal pain; (3) constipation or diarrhoea; (4) overall health of patients is general good or show with the general neurosis.(5) the spontaneous wriggling of colon is unusual, and intestinal sensitivity increases.(6) internal organs hyperpathia etc.
4, other relevant diseases comprise: functional bowel disorder (functional diarrhea, functional constipation), acute and chronic functional abdominal pain or abdominal distention or with the stomach symptom, periodically stomachache or abdominal distention, functional dyspepsia, gastropathy stomach discomfort etc.
The result of study of the animal pharmacodynamics of this compositions is as follows:
The defecation of 1 pair of model of spleen deficiency animal of drug efficacy study and the recovery of body weight and the influence of motilin.
The result of study of animal pharmacology: (1) influences experiment material 1.1 experimental drugs to the recovery of the defecation of model of spleen deficiency animal and body weight and motilin: plan side's (Radix Bupleuri 10 grams certainly, the Radix Paeoniae Alba 9 grams, Rhizoma Chuanxiong 6 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Poria 9 grams, Radix Glycyrrhizae 6 grams).Concentrated solution decocts twice on request by prescription drug, is concentrated into 1 gram crude drug/ml (middle dosage) behind an amount of ethanol precipitation, 3 gram crude drug/ml (high dose), and 5 ℃ of storages are standby; 1.2 laboratory animal: the SD kind rat that grows up, 180～220g.2 experimental techniques, 2.1 grouping experiments
Matched group: get 10 of healthy rats, intraperitoneal injection of saline is an amount of, continuous 10 days.And in whenever
Day, 9:00,16:00 gavaged each 2ml of normal saline.Continuous 20 days, record was observed.
Model preparation: get rats by intraperitoneal injection reserpine injection 0.5mg kg
-1d
-1Continuous 10 days.
9:00,16:00 gavage each 2ml of normal saline every day.
Natural recovering group: 10 of delivery type rats, 9:00,16:00 gavage each 2ml of normal saline every day.
Continuous 10 days.
From plan side's low dose group: 10 of delivery type rats, 9:00,16:00 gavage from plan side dense every day
Each 2ml of liquid (1g/ml) that contracts, continuous 10 days.
From plan side's high dose group: 10 of delivery type rats, 9:00,16:00 gavage from plan side dense every day
Each 2ml of liquid (3g/ml) that contracts, continuous 10 days.
The positive drug matched group: 10 of delivery type rats, in every day 9:00,16:00 with 1g Kg
-1Agent
Amount gavages the dioctahedral smectite suspension, continuous 10 days.2.2 judge index as a result
The model situation is observed: engender in various degree diarrhoea, crissum dirt behind the modeling rat injection reserpine
Dirty.To the tenth day all a large amount of loose stools of each group, appetite descended.
Index is selected: write down situations such as each treated animal body weight, appetite, feces.Selecting the sings and symptomses such as time of animal appetite, body weight, recovery normal defecation is judge index.The results are shown in Table 1, table 2.Other gets motilin (MTL) and is the auxiliary judgment index.Observe the mucosa injury situation of gastrointestinal tissue simultaneously.Each treated animal experiment finishes back fasting 16 hours, and sacrificed by decapitation is got intestinal juice, blood plasma, jejunum, the freezing preservation of inferior colliculus cerebral tissue, presses kit method and measures MTL, the results are shown in Table 3.Get gastrointestinal tissue, naked eyes, light microscopic, transmission electron microscope observing mucosa injury situation the results are shown in Table 4.2.4 adopt two groups of t check carrying out statistical analysiss between the date processing mean in twos.3 results
Middle and high dosage can significantly improve body weight (P＜0.05) and the appetite (P＜0.05) of animal pattern from plan side's group and positive drug matched group, and plan side's group is significantly increased by (P＜0.05) (table 1, table 2) than the positive drug matched group certainly. middle and high dosage all can accelerate to improve the disorderly symptom of animal defecation from plan side's group, positive drug matched group, from rapid-action in dioctahedral smectite (table 3) with side's group.Middle and high dosage significantly improves MTL content (P＜0.05) (table 4) in animal pattern body fluid and the tissue from intending Fang Zuneng.Middle and high dosage all can obviously recover model drug to gastrointestinal mucosa cells injury (table 5) from plan side's group and positive drug matched group.
This result of study shows: animal model has tangible diarrhoea, loose stool, feces viscous not well, degradation symptom under appetite, body weight, the MTL.But there is no gastrointestinal mucosa before and after the medication obviously damages.Can obviously improve the general situation of reserpinization rat model (body weight, appetite, defecation) (P＜0.05) from plan side and dioctahedral smectite, intend to significantly improve MTL content (P＜0.05) in animal pattern body fluid and the tissue certainly; At aspects such as general situation, normal defecation recovery natural law, MTL significant advantage (P＜0.05) is all arranged than the dioctahedral smectite matched group from plan side's treatment group.Recover aspects such as natural law, body weight, MTL at defecation than dioctahedral smectite matched group be significantly improved (P＜0.05) from plan side's treatment group.Pretend medicine for treatment, help patient's rehabilitation for IBS.(2) to the research at the drug effect position of gastrointestinal motility regulating action.Method: adopt intestine in vitro to observe from of the influence of the different extract parts in plan side to the isolated small intestines of rabbits motion.Material 11 trial drugs boil twice through decocting from the side's of plan medicine, 30 minutes/each, filter, centrifugal, after concentrating, behind different organic solvent extractions, tell the molten position of water extraction alcohol, chloroform extract, chloroform extract 1, chloroform extract 2, ethyl acetate extract, ethyl acetate extract 1, ethyl acetate extract 2, ethyl acetate extract 3, n-butanol portion 1, n-butanol portion 2, the insoluble position of n-butyl alcohol, be mixed with debita spissitudo with distilled water during test and use.
Sketch map is separated at the different chemical position
Chinese medicine compound
↓
Water extraction
The molten position of ↓ water extracting alcohol ← water extract → ether position
↓
Insoluble part → the chloroform extract of ether → chloroform extract 2, chloroform extract 1
↓
Insoluble part → the ethyl acetate extract of chloroform → ethyl acetate extract 1, ethyl acetate extract 2,
Ethyl acetate extract 3
↓
Ethyl acetate part → n-butanol portion → n-butanol portion 1, n-butanol portion 2
↓
Rabbit, body weight 20～2.5kg plant in the insoluble position of n-butyl alcohol 13 animal New Zealand.The preparation reference literature method of 14 method isolated small intestines of rabbits, desk-top self-balancing recorder is traced curve movement, observe the variation of administration front and back intestinal tube curve movement: 1. relatively from the influence of each extract part of plan side to the duodenum spontaneous activity, 5 minutes intestinal tube shrinkage amplitudes suppress percentage rate after the calculating administration.2. at barium chloride (BaCl
2, 20% 0.1ml) cause on the basis of the tetanic property of rat small intestine in vitro contraction, observe the antagonism of each sample, obtain intestinal tube tension force height is suppressed percentage rate.3. cause the antagonism of observation sample on the obvious basis that suppresses of rat small intestine in vitro at adrenalin hydrochloride (0.1ml), obtain medicine intestinal tube shrinkage amplitude increment rate.The influence of 2.1 pairs of rabbit duodenums of 2 results spontaneous activity
From plan side's water extract, the molten position of water extraction alcohol the stripped duodenum spontaneous activity of rabbit is the inhibition influence, shows as shrinkage amplitude and reduce, frequency reduces, and tension force descends.Dosage hour mainly shows shrinkage amplitude and reduces, and frequency and tension variation are not obvious.Above dosage suppresses percentage rate to the intestinal tube shrinkage amplitude and is respectively 69.0 ± 27.3% (n=10) and 81.4 ± 12.0% (n=10).Spontaneous activity is inhibition influence to duodenum from plan side's ethyl acetate extract, chloroform extract, n-butanol extraction position, act on similarly to the water extract, mainly shows as the shrinkage amplitude minimizing.When dosage was big, frequency reduced to some extent, and tension force slightly descends, and its action intensity is relevant with dosage.The three compares, and ethyl acetate is suitable with the chloroform extract action intensity, a little less than the n-butanol portion effect.The insoluble position of n-butyl alcohol is not obvious to duodenum spontaneous activity effect.2.2 the effect of antagonism acetylcholine, barium chloride
From plan side's water extract (35mg/ml), the water extraction molten position of alcohol (35mg/ml) acetylcholine, barium chloride are caused that the contraction of the tetanic property of intestinal tube all has obvious antagonism, mainly shows as tensile force and obviously descends.Antagonism percentage rate to acetylcholine is respectively 66.9 ± 11.3% (n=10), 70.1 ± 9% (n=10); Antagonistic rate to barium chloride is respectively 53.4 ± 11.2% (n=10), 48.5 ± 9.6% (n=10).From plan side's ethyl acetate extract, chloroform extract, n-butanol portion acetylcholine is caused that the contraction of the tetanic property of intestinal tube all has tangible antagonism, the tension force that mainly shows as intestinal tube obviously descends, and action intensity is relevant with dosage.The three compares, and the action intensity of chloroform extract and ethyl acetate extract is suitable, a little less than the effect of n-butanol portion.
Chloroform extract 1, chloroform extract 2, ethyl acetate extract 1, ethyl acetate extract 2 have the effect of tangible antagonism acetylcholine, barium chloride, and action intensity all significantly strengthens than chloroform extract or ethyl acetate extract.Ethyl acetate extract 3 does not have this effect.N-butanol portion 2 pairs of acetylcholine, barium chlorides cause that the contraction of the tetanic property of intestinal tube all has obvious antagonism, but intensity a little less than, be lower than chloroform extract or ethyl acetate extract.2.3 adrenolytic
From plan side's water extract, n-butanol portion, the insoluble position of n-butyl alcohol epinephrine is caused that the obvious inhibition of rat small intestine in vitro all shows certain antagonism, antagonistic rate is respectively 23.8 ± 8.4%, 13.5 ± 53%, 12.7 ± 4.7% (n=10), mainly show as add reagent after, shrinkage amplitude has certain increasing.Ethyl acetate extract, chloroform extract, the molten position of water extraction alcohol all do not have the antiadrenergic drug effect.
1 pair of epinephrine of n-butanol portion causes that the obvious inhibition of rat small intestine in vitro shows intensive antagonism, and action intensity is than the remarkable enhancing of n-butanol portion.2 pairs of epinephrines of n-butanol portion cause that the obvious inhibition of rat small intestine in vitro do not have antagonism.3 discuss clinical being used in various degree gastrointestinal motility disorder (show as the hyperfunction of gastrointestinal motility or weaken) from plan sides.The method that we adopt Chemical Decomposition and drug efficacy study to combine is studied.The result shows that tentatively spontaneous activity is the inhibition influence to isolated small intestines of rabbits for the side's of plan chloroform extraction position, ethyl acetate extract, n-butanol portion, water extract certainly.Cause that at acetylcholine or barium chloride all there is antagonism at above-mentioned position on the basis of the tetanic property of rat small intestine in vitro contraction, wherein stronger with chloroform extract, ethyl acetate extract effect.No matter the insoluble position of n-butyl alcohol is all not have tangible influence to the spontaneous activity of small intestinal or to the effect of acetylcholine, barium chloride.Cause that at epinephrine except that n-butanol portion had certain adrenolytic, all the other positions did not have this effect on the obvious basis that suppresses of rat small intestine in vitro.
FF chloroform extract 1, chloroform extract 2, ethyl acetate extract 1, the ethyl acetate extract 2 of each effective site after further separating shows acetylcholine, barium chloride caused the more intensive antagonism of the tetanic property of intestinal tube contraction; 1 pair of epinephrine of FF n-butanol portion causes the more intensive antagonism of obvious inhibition of rat small intestine in vitro.
The appetite of each treated animal changes after table 1 medication
*P＜0.05vs natural recovering group, aP＜0.05vs positive drug matched group
Each treated animal body weight change of table 2
*P＜0.05vs natural recovering group, aP＜0.05vs positive drug matched group
Table 3 defecation state observation
| Group | Feces recovery normal time (my god) |
| Matched group | |
| Natural recovering group | ????11 |
| From plan side's high dose group | ????5 |
| Dosage group in plan side | ????5 |
| The positive drug matched group | ????7 |
Table 4 MTL is changes of contents group blood plasma intestinal juice hypothalamus jejunum tissue in animal body fluid and tissue
Ng/L ng/L ng/L ng/L matched group 231.14 ± 77.28 624.05 ± 29.47 32.94 ± 59.72 ± 5.05
2.18 natural recovering group 168.75 ± 31.40 483.57 ± 41.26 20.17 ± 41.62 ± 4.91
5.40 high agent 255.08 ± 610.39 ± 28.62 ± 55.21 ± amount in plan side group 29.59 certainly
*46.29
*3.66
*7.27
*A is agent 220.61 ± 654.96 ± 30.57 ± 68.40 ± amount group 51.42 in plan side
*30.51
*7.04
*4.25
*The a positive drug shines group 27.93 to 192.31 ± 499.35 ± 38.16 18.73 ± 3861 ± 3.19
*5.17
*P＜0.05vs natural recovering group; AP＜0.05vs positive drug matched group
The damage of table 5 gastrointestinal mucosa is observed the normal normal mucosa epithelial cell of the normal normal natural recovering group of group naked eyes light microscopic Electronic Speculum matched group and is arranged loose, few
Measuring the normal normal mucosa epithelial cell of the natural recovering group that comes off arranges loose, few
Amount comes off approaching from the normal normal mucosa epithelial cell of the side's of plan high dose group
Matched group, it is approaching not have the normal normal mucosa epithelial cell of dosage group that comes off in plan side
Matched group, it is approaching not have the normal normal mucosa epithelial cell of positive drug matched group that comes off
Matched group, not having comes off faces urine use observation
Irritable bowel syndrome (IBS) is common digestive tract non-organic disease, and clinical symptoms is with irregular stomachache, abdominal distention, diarrhoea, and the stool character changes and defecation frequency increases and is main performance, and existing still do not have an ideal Therapeutic Method.The medicine of clinical treatment IBS is the alleviation at a certain symptom basically at present, as analgesic (as calcium ion antagonist), diarrhea and gastrointestinal tract dynamia medicine etc.At also not having certain clear and definite medicine can cure this situation of IBS at present, so should adopt the principle of Comprehensive Treatment to the treatment of IBS.The invention provides the compound (Radix Bupleuri 10 grams, the Radix Paeoniae Alba 9 grams, Rhizoma Chuanxiong 6 grams, Radix Pseudostellariae 6 grams, the Rhizoma Atractylodis Macrocephalae 9 grams, Poria 9 grams, Radix Glycyrrhizae 6 grams) of Chinese medicine, take dispersing the stagnated live-QI to relieve the stagnation of QI, press down intestinal antidiarrheal; The sweet light Therapeutic Principle who holds up spleen, yin nourishing to help fortune carries out prescription.On the basis of theory of Chinese medical science and pharmacological evaluation, through our clinical observation, be used for the treatment of IBS and other gastrointestinal function disorders, effect is better.The result is as follows: the selection of control drug:
In recent years there is the many cases clinical report to adopt dioctahedral smectite treatment IBS to obtain better effects, dioctahedral smectite all has the improvement effect to the multiple symptom of IBS, particularly aspect times of defecation and stool character, can be alleviated rapidly and improve at symptom after taking medicine, stool can recover normal after most patients 3-4 days.The case choice criteria:
Select the 50 routine irritable bowel syndrome courses of disease the patient more than 1 month, case is selected: by the irritable bowel syndrome case choice criteria of the whole nation, Chengdu in 1986 chronic diarrhea academic discussion formulation.All cases are through routine blood test, just routine, liver function, blood glucose, liver and gall pancreas B ultrasonic, fibro-colonoscope or intestinal barium agent radiography are got rid of organic disease.Clinical manifestation can be alleviated with stomachache behind abdominal distention, borborygmus, stomachache, the defecation based on diarrhoea.Therapeutic process:
Male's 33 examples in the case, women's 17 examples; Be divided into treatment and organize 40 examples, matched group 10 examples.Two groups close in sex, age, clinical manifestation, and comparability is arranged.Treatment group: use from plan side's potion every day.2 week back doing well,improving person every days of treatment 2 times, 2 weeks of reuse.With the foundation of 4 weeks back clinical manifestation as the curative effect judgement.Matched group: dioctahedral smectite 3 restrains once, and every day 3 times, the course of treatment is the same.Be nonrandom grouping, treat have a blood test after 4 weeks routine, liver function, further consultation 1 time weekly in the therapeutic process understands that symptom changes, defecation character and number of times, looks into just conventional.Efficacy evaluation
Produce effects: diarrhoea stops, and simultaneous phenomenon is obviously alleviated.Effectively: diarrhoea is obviously alleviated, and every day, defecation was 2 times, and simultaneous phenomenon takes a turn for the better.Invalid: as not reach above-mentioned standard.The result observes
Organize from plan side: 40 examples, produce effects 21 examples (52.5%), effective 12 examples (30%), invalid 7 examples (17.5%), total effective rate 82.5％。Matched group 20 examples, produce effects 5 examples (25%), effective 7 examples (35%), invalid 8 examples (40%), total effective rate 60%.Curative effect is higher than dioctahedral smectite from plan side, and treatment the fastest onset in plan side's is 5 days certainly.3 all stable curative effect show, stomachache and malaise symptoms significantly reduce, and function of intestinal canal improves (comprise that times of defecation and sense of urgency reduce, the stool character is improved), and the while was maintained during whole medication in doing well,improving appeared at around medication preceding.Invalid case extends the period of treatment and also can not improve curative effect, and two groups of medications there is no obvious adverse reaction, treatment back routine blood test, the equal no change of liver function.
This compositions is representing unique effect and advantage aspect the IBS in treatment, tally with the national condition sturdy basis and prospect preferably of exploitation treatment IBS modern Chinese medicine from the Chinese medicine clinical proved recipe.
The specific embodiment
Embodiment 1: Radix Bupleuri 9 grams, the Radix Paeoniae Alba 9, Rhizoma Chuanxiong 6, the Rhizoma Atractylodis Macrocephalae 9, Poria 9 grams, Radix Glycyrrhizae 6 grams.
Embodiment 2: Radix Bupleuri 10 grams, the Radix Paeoniae Alba 9, Rhizoma Chuanxiong 6, the Rhizoma Atractylodis Macrocephalae 6, Poria 6 grams, Radix Glycyrrhizae 3 grams.
Embodiment 3: Radix Bupleuri 12 grams, the Radix Paeoniae Alba 9, Rhizoma Chuanxiong 6, Radix Pseudostellariae 10, the Rhizoma Atractylodis Macrocephalae 6, Poria 3, Radix Glycyrrhizae 5 grams.
Embodiment 4: Radix Pseudostellariae 18, the Radix Paeoniae Alba 15, Rhizoma Chuanxiong 15, Radix Bupleuri 10 grams, the Rhizoma Atractylodis Macrocephalae 15, Poria 9 grams, Radix Glycyrrhizae 9 grams.
Embodiment 5: Radix Bupleuri 12 grams, the Radix Paeoniae Alba 9, Rhizoma Chuanxiong 6, Radix Pseudostellariae 10, the Rhizoma Atractylodis Macrocephalae 6, Poria 3, Radix Glycyrrhizae 5 grams.Pericarpium Citri Reticulatae 6, Fructus Aurantii Immaturus 6.)
Embodiment 6: Radix Bupleuri 10 grams, the Radix Paeoniae Alba 15, Rhizoma Chuanxiong 5, the Rhizoma Atractylodis Macrocephalae 20, Poria 15 grams, Radix Glycyrrhizae 8 grams.
Embodiment 7: Radix Bupleuri 10 grams, the Radix Paeoniae Alba 15, Rhizoma Chuanxiong 5, the Rhizoma Atractylodis Macrocephalae 20, Poria 15 grams, Radix Glycyrrhizae 8 grams.Pericarpium Citri Reticulatae.
Embodiment 8: Radix Bupleuri 12, Radix Scutellariae 9, Radix Codonopsis 9, Radix Glycyrrhizae 6, Fructus Aurantii Immaturus 6, the Radix Paeoniae Alba 12.
Embodiment 9: Radix Bupleuri 9 grams, and the Radix Paeoniae Alba 18,, the Rhizoma Atractylodis Macrocephalae 12, Poria 6 grams, Radix Glycyrrhizae 9 grams.Pericarpium Citri Reticulatae 9
Embodiment 10: the Rhizoma Atractylodis Macrocephalae 9, the Radix Paeoniae Alba 6, Pericarpium Citri Reticulatae 6, Radix Codonopsis 6, Radix Glycyrrhizae 4.5, Poria 3.
Embodiment 11: the Rhizoma Atractylodis Macrocephalae 12, the Radix Paeoniae Alba 9, Radix Saposhnikoviae 6, Semen Myristicae 6, Fructus Evodiae 6, Fructus Schisandrae Chinensis 6, Radix Glycyrrhizae 3, Poria 9.
Embodiment 12: the Radix Paeoniae Alba 15, Radix Glycyrrhizae 9, Poria 6, Fructus Mume 9, Rhizoma Coptidis 3, Ramulus Cinnamomi 3, Radix Pseudostellariae 6.
Embodiment 13: the Radix Paeoniae Alba 20, Radix Glycyrrhizae 9, Ramulus Cinnamomi 9, the Rhizoma Atractylodis Macrocephalae 9, Poria 9, Pericarpium Citri Reticulatae 6, Radix Curcumae 3.
Embodiment 14: Radix Codonopsis 18, the Rhizoma Atractylodis Macrocephalae 9, Poria 9 grams, Radix Glycyrrhizae 6 grams.Radix Platycodonis 9, Rhizoma Coptidis 3, the Radix Aucklandiae 3, Fructus Crataegi 3, Massa Medicata Fermentata 3, Fructus Aurantii Immaturus 3, Pericarpium Citri Reticulatae 3.
Embodiment 15: the Radix Paeoniae Alba 18, the Rhizoma Atractylodis Macrocephalae 15, Semen Myristicae 12, Rhizoma Chuanxiong 6, Pericarpium Citri Reticulatae 6, Radix Glycyrrhizae 6, Ramulus Cinnamomi 3, Rhizoma Coptidis 3.
Claims (9)
1, a kind of Chinese medicine composition for the treatment of the bowel dysfunction disease is characterized in that, comprises in the component:
Radix Bupleuri 6-15 gram
Radix Paeoniae Alba 5-20 gram
Rhizoma Chuanxiong 3-10 gram
Rhizoma Atractylodis Macrocephalae 6-20 gram
Poria 6-12 gram
Radix Glycyrrhizae 5-20 gram.
According to the Chinese medicine composition of the described treatment bowel dysfunction of claim 1 disease, it is characterized in that 2, the composition of compositions is:
Radix Bupleuri 8-12 gram
Radix Paeoniae Alba 9-12 gram
Rhizoma Chuanxiong 5-9 gram
Rhizoma Atractylodis Macrocephalae 9-15 gram
Poria 6-12 gram
Radix Glycyrrhizae 6-15 gram.
3, according to the Chinese medicine composition of claim 1 or 2 described treatment bowel dysfunction diseases, it is characterized in that, also contain in the following two class medicines any one or multiple:
Radix Codonopsis, Fructus Mume, Fructus Aurantii Immaturus, Radix Saposhnikoviae, Pericarpium Citri Reticulatae, Radix Pseudostellariae, Ramulus Cinnamomi, Rhizoma Cimicifugae, Semen Myristicae, Fructus Schisandrae Chinensis;
The Radix Astragali, Radix Ginseng, Radix Puerariae, Ramulus Uncariae Cum Uncis, Radix Angelicae Sinensis, Fructus Jujubae, Rhizoma Zingiberis Recens, Rhizoma Cyperi, the Rhizoma Pinelliae, Radix Curcumae.
4, according to the Chinese medicine composition of the described treatment bowel dysfunction of claim 3 disease, it is characterized in that also having the Radix Aucklandiae 6 grams in the compositions.
5, according to the Chinese medicine composition of the described treatment bowel dysfunction of claim 3 disease, it is characterized in that, on basic side basis, increase a kind of in the following scheme combination of components: (1), increase Radix Pseudostellariae 10～18 grams, or, (2), Radix Pseudostellariae 10～18 grams, Pericarpium Citri Reticulatae, each 6 gram of Fructus Aurantii Immaturus; Or (3), Pericarpium Citri Reticulatae 6 grams～9 grams, or (4), Radix Scutellariae 9 grams, Radix Codonopsis 9 grams, Fructus Aurantii Immaturus 6 grams, Rhizoma Cimicifugae 3 grams, or (5), Pericarpium Citri Reticulatae, each 6 gram of Radix Codonopsis.
6, according to the Chinese medicine composition of the described treatment bowel dysfunction of claim 3 disease, it is characterized in that also having Radix Saposhnikoviae 6 grams, Semen Myristicae 6 grams, Radix Puerariae 9 grams, Fructus Schisandrae Chinensis 6 grams in the compositions.
7, according to the Chinese medicine composition of the described treatment bowel dysfunction of claim 3 disease, it is characterized in that, on basic side basis, increase a kind of in the following combination of components: (1), Fructus Mume 9 grams, Rhizoma Coptidis 3 grams, Ramulus Cinnamomi 3 grams, Radix Pseudostellariae 6 grams; Or (2), Semen Myristicae 12 grams, Pericarpium Citri Reticulatae 6 grams, Ramulus Cinnamomi 6 grams, Rhizoma Coptidis 3 grams; Or (3), Ramulus Cinnamomi 9 grams, Pericarpium Citri Reticulatae 6 grams, Radix Curcumae 3 grams.
8, according to the Chinese medicine composition of the described treatment bowel dysfunction of claim 3 disease, it is characterized in that also having in the compositions: Radix Codonopsis 18 grams, Radix Platycodonis 9 grams, Rhizoma Coptidis 3 grams, the Radix Aucklandiae 3 grams, Fructus Crataegi 3 grams, Massa Medicata Fermentata 3 grams, Fructus Aurantii Immaturus 3 grams, Pericarpium Citri Reticulatae 3 grams.
9, the dosage form of the Chinese medicine composition of claim 1 or 2 described treatment bowel dysfunction diseases comprises:
Direct or purified granule, capsule, tablet, oral liquid, parenteralia, percutaneous or the mucosal preparation of the suitable pharmaceutic adjuvant preparation of back adding, the suppository of rectally of separating of the extract of compositions, or
The combination of Chinese medicine thing adds granule, capsule, tablet, percutaneous or the mucosal preparation of suitable pharmaceutic adjuvant preparation, the suppository of rectally after crushed, or
Compositions extract direct or purified separation back and the direct ground product of medicine make up granule, capsule, tablet, percutaneous or the mucosal preparation of back preparation, the suppository of rectally.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03112782 CN1250255C (en) | 2003-01-28 | 2003-01-28 | Chinese herbal medicine combination for treating disease of disorder of bowels's function and its product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03112782 CN1250255C (en) | 2003-01-28 | 2003-01-28 | Chinese herbal medicine combination for treating disease of disorder of bowels's function and its product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1430999A true CN1430999A (en) | 2003-07-23 |
| CN1250255C CN1250255C (en) | 2006-04-12 |
Family
ID=4790300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03112782 Expired - Fee Related CN1250255C (en) | 2003-01-28 | 2003-01-28 | Chinese herbal medicine combination for treating disease of disorder of bowels's function and its product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1250255C (en) |
Cited By (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100387264C (en) * | 2004-12-27 | 2008-05-14 | 包宗昭 | Suppository of Chinese traditional medicine for improving intestine motivity and preparation method |
| CN102228550A (en) * | 2011-06-29 | 2011-11-02 | 北京天地外医药科技有限公司 | Pharmaceutical composition for treating irritable bowel syndrome |
| CN101199639B (en) * | 2007-12-20 | 2011-12-14 | 北京天力正元医药技术开发有限公司 | Chinese medicine for treating irritable |
| CN101700289B (en) * | 2009-11-02 | 2012-02-15 | 南京师范大学 | Traditional Chinese medicine extract composition for treating gastrointestinal dysfunction or irritable bowel syndrome (IBS), and preparation method and applications thereof in preparation of medicaments |
| CN102512624A (en) * | 2011-11-28 | 2012-06-27 | 李守玮 | Chinese medicine soup with functions of dispelling flatulence and strengthening stomach for treating functional dyspepsia |
| CN102552511A (en) * | 2012-03-23 | 2012-07-11 | 刘洁 | Medicament for treating diarrhea |
| CN102657727A (en) * | 2012-05-20 | 2012-09-12 | 王光华 | Medicine for treating colonitis and preparation method thereof |
| CN103463417A (en) * | 2013-09-30 | 2013-12-25 | 丰建君 | Traditional Chinese medicine used for treating irritable bowel syndrome |
| CN103610801A (en) * | 2013-11-19 | 2014-03-05 | 安徽宝芝堂药业有限公司 | Traditional Chinese medicine composition for treating typhia and heat syncope |
| CN103610804A (en) * | 2013-12-11 | 2014-03-05 | 张晨 | Chinese medicinal soup decoction for treating chronic colitis |
| CN103961391A (en) * | 2014-04-17 | 2014-08-06 | 陈新灵 | Medicine composition for treating gastrointestinal psychoneurosis |
| CN103977111A (en) * | 2014-05-28 | 2014-08-13 | 赵润田 | Traditional Chinese medicine for treating chronic hepatitis |
| CN104257799A (en) * | 2014-10-09 | 2015-01-07 | 浙江金大康动物保健品有限公司 | Veterinary drug for treating high-mortality lactation piglet diarrhea |
| CN104524481A (en) * | 2015-01-30 | 2015-04-22 | 山东省立医院 | Traditional Chinese medicine for treating irritable bowel syndrome and preparation method thereof |
| CN104548019A (en) * | 2014-12-31 | 2015-04-29 | 东莞市智健医疗科技有限公司 | Use of traditional Chinese medicine preparation in preparation of medicine for treating diarrhea after chemotherapy |
| CN104666623A (en) * | 2015-03-02 | 2015-06-03 | 陈景波 | Gastrointestinal drug and preparation method thereof |
| CN105031587A (en) * | 2015-08-14 | 2015-11-11 | 任德旺 | Chinese herba preparation for curing gastrointestinal diseases |
| CN105497879A (en) * | 2015-12-31 | 2016-04-20 | 中悦民安（北京）科技发展有限公司 | Anti-stress traditional Chinese medicine compound capable of improving product flavor |
| CN105853982A (en) * | 2016-05-26 | 2016-08-17 | 成都中医药大学附属医院 | Pharmaceutical composition for preventing and treating functional gastrointestinal disorder and preparation method thereof |
| CN105878754A (en) * | 2013-08-19 | 2016-08-24 | 刘伟 | Preparation method of bowel-cleaning drug for preoperative night |
| CN105902928A (en) * | 2016-05-30 | 2016-08-31 | 苏州市天灵中药饮片有限公司 | Intestines-astringing and diarrhea-checking capsules and preparation method thereof |
| CN106913825A (en) * | 2017-04-12 | 2017-07-04 | 柳州联海科技有限公司 | Special moxa-moxibustion pharmaceutical composition of a kind of moxibustion instrument and preparation method thereof |
| CN108295135A (en) * | 2018-04-03 | 2018-07-20 | 河南中医药大学 | A kind of Chinese medicine composition for invigorating the spleen for eliminating dampness |
| CN108295126A (en) * | 2018-03-09 | 2018-07-20 | 广东松山湖臻德生物医药科技有限公司 | A kind of Chinese medicine composition and its preparation method and application for treating irritable bowel syndrome |
| CN108403820A (en) * | 2018-05-28 | 2018-08-17 | 新乡医学院 | It is a kind of to be used to treat Chinese medical extract of gastrointestinal disease and preparation method thereof |
| CN108617923A (en) * | 2018-04-27 | 2018-10-09 | 北京晋师傅工贸有限公司 | A kind of hollow peach offered as a birthday present shape millet cake of health |
| CN108686070A (en) * | 2018-07-16 | 2018-10-23 | 资兴市泰坤农林生态产业有限公司 | A kind of livestock stomach strengthening and digestion promoting composition and preparation method thereof |
| CN109731064A (en) * | 2018-11-29 | 2019-05-10 | 王丽 | A kind of Chinese materia medica preparation for alleviating belly flatulence |
| CN109731092A (en) * | 2019-02-28 | 2019-05-10 | 河北省中医院 | A kind of Chinese medicine composition and preparation method thereof for treating constipation-predominant of irritable bowel syndrome |
| CN110393749A (en) * | 2018-04-24 | 2019-11-01 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | A kind of Chinese medicine composition of external curing irritable bowel syndrome |
| US11452755B2 (en) * | 2007-10-25 | 2022-09-27 | Yale University | Use of PHY906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome |
-
2003
- 2003-01-28 CN CN 03112782 patent/CN1250255C/en not_active Expired - Fee Related
Cited By (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100387264C (en) * | 2004-12-27 | 2008-05-14 | 包宗昭 | Suppository of Chinese traditional medicine for improving intestine motivity and preparation method |
| US11452755B2 (en) * | 2007-10-25 | 2022-09-27 | Yale University | Use of PHY906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome |
| CN101199639B (en) * | 2007-12-20 | 2011-12-14 | 北京天力正元医药技术开发有限公司 | Chinese medicine for treating irritable |
| CN101700289B (en) * | 2009-11-02 | 2012-02-15 | 南京师范大学 | Traditional Chinese medicine extract composition for treating gastrointestinal dysfunction or irritable bowel syndrome (IBS), and preparation method and applications thereof in preparation of medicaments |
| CN102228550A (en) * | 2011-06-29 | 2011-11-02 | 北京天地外医药科技有限公司 | Pharmaceutical composition for treating irritable bowel syndrome |
| CN102228550B (en) * | 2011-06-29 | 2013-02-20 | 北京天地外医药科技有限公司 | Pharmaceutical composition for treating irritable bowel syndrome |
| CN102512624A (en) * | 2011-11-28 | 2012-06-27 | 李守玮 | Chinese medicine soup with functions of dispelling flatulence and strengthening stomach for treating functional dyspepsia |
| CN102552511A (en) * | 2012-03-23 | 2012-07-11 | 刘洁 | Medicament for treating diarrhea |
| CN102657727A (en) * | 2012-05-20 | 2012-09-12 | 王光华 | Medicine for treating colonitis and preparation method thereof |
| CN105878754A (en) * | 2013-08-19 | 2016-08-24 | 刘伟 | Preparation method of bowel-cleaning drug for preoperative night |
| CN103463417B (en) * | 2013-09-30 | 2015-06-10 | 丰建君 | Traditional Chinese medicine used for treating irritable bowel syndrome |
| CN103463417A (en) * | 2013-09-30 | 2013-12-25 | 丰建君 | Traditional Chinese medicine used for treating irritable bowel syndrome |
| CN103610801A (en) * | 2013-11-19 | 2014-03-05 | 安徽宝芝堂药业有限公司 | Traditional Chinese medicine composition for treating typhia and heat syncope |
| CN103610804B (en) * | 2013-12-11 | 2015-04-15 | 邢吉华 | Chinese medicinal soup decoction for treating chronic colitis |
| CN103610804A (en) * | 2013-12-11 | 2014-03-05 | 张晨 | Chinese medicinal soup decoction for treating chronic colitis |
| CN103961391B (en) * | 2014-04-17 | 2016-08-31 | 陈新灵 | A kind of pharmaceutical composition treating gastrointestinal neurosis |
| CN103961391A (en) * | 2014-04-17 | 2014-08-06 | 陈新灵 | Medicine composition for treating gastrointestinal psychoneurosis |
| CN103977111A (en) * | 2014-05-28 | 2014-08-13 | 赵润田 | Traditional Chinese medicine for treating chronic hepatitis |
| CN103977111B (en) * | 2014-05-28 | 2016-04-13 | 吉林大学 | A kind of Chinese medicine for the treatment of chronic hepatitis |
| CN104257799A (en) * | 2014-10-09 | 2015-01-07 | 浙江金大康动物保健品有限公司 | Veterinary drug for treating high-mortality lactation piglet diarrhea |
| CN104548019A (en) * | 2014-12-31 | 2015-04-29 | 东莞市智健医疗科技有限公司 | Use of traditional Chinese medicine preparation in preparation of medicine for treating diarrhea after chemotherapy |
| CN104524481A (en) * | 2015-01-30 | 2015-04-22 | 山东省立医院 | Traditional Chinese medicine for treating irritable bowel syndrome and preparation method thereof |
| CN104524481B (en) * | 2015-01-30 | 2018-01-12 | 山东省立医院 | A kind of Chinese medicine for treating IBS and preparation method thereof |
| CN104666623A (en) * | 2015-03-02 | 2015-06-03 | 陈景波 | Gastrointestinal drug and preparation method thereof |
| CN105031587A (en) * | 2015-08-14 | 2015-11-11 | 任德旺 | Chinese herba preparation for curing gastrointestinal diseases |
| CN105497879A (en) * | 2015-12-31 | 2016-04-20 | 中悦民安（北京）科技发展有限公司 | Anti-stress traditional Chinese medicine compound capable of improving product flavor |
| CN105853982A (en) * | 2016-05-26 | 2016-08-17 | 成都中医药大学附属医院 | Pharmaceutical composition for preventing and treating functional gastrointestinal disorder and preparation method thereof |
| CN105853982B (en) * | 2016-05-26 | 2019-12-31 | 成都中医药大学附属医院 | Pharmaceutical composition for preventing and treating functional gastrointestinal diseases and preparation method thereof |
| CN105902928A (en) * | 2016-05-30 | 2016-08-31 | 苏州市天灵中药饮片有限公司 | Intestines-astringing and diarrhea-checking capsules and preparation method thereof |
| CN106913825A (en) * | 2017-04-12 | 2017-07-04 | 柳州联海科技有限公司 | Special moxa-moxibustion pharmaceutical composition of a kind of moxibustion instrument and preparation method thereof |
| CN108295126A (en) * | 2018-03-09 | 2018-07-20 | 广东松山湖臻德生物医药科技有限公司 | A kind of Chinese medicine composition and its preparation method and application for treating irritable bowel syndrome |
| CN108295126B (en) * | 2018-03-09 | 2021-05-14 | 东莞市中医院 | Traditional Chinese medicine composition for treating irritable bowel syndrome and preparation method and application thereof |
| CN108295135A (en) * | 2018-04-03 | 2018-07-20 | 河南中医药大学 | A kind of Chinese medicine composition for invigorating the spleen for eliminating dampness |
| CN110393749A (en) * | 2018-04-24 | 2019-11-01 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | A kind of Chinese medicine composition of external curing irritable bowel syndrome |
| CN108617923A (en) * | 2018-04-27 | 2018-10-09 | 北京晋师傅工贸有限公司 | A kind of hollow peach offered as a birthday present shape millet cake of health |
| CN108403820A (en) * | 2018-05-28 | 2018-08-17 | 新乡医学院 | It is a kind of to be used to treat Chinese medical extract of gastrointestinal disease and preparation method thereof |
| CN108686070A (en) * | 2018-07-16 | 2018-10-23 | 资兴市泰坤农林生态产业有限公司 | A kind of livestock stomach strengthening and digestion promoting composition and preparation method thereof |
| CN109731064A (en) * | 2018-11-29 | 2019-05-10 | 王丽 | A kind of Chinese materia medica preparation for alleviating belly flatulence |
| CN109731092A (en) * | 2019-02-28 | 2019-05-10 | 河北省中医院 | A kind of Chinese medicine composition and preparation method thereof for treating constipation-predominant of irritable bowel syndrome |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1250255C (en) | 2006-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1250255C (en) | Chinese herbal medicine combination for treating disease of disorder of bowels's function and its product | |
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN109045201B (en) | Traditional Chinese medicine composition for treating chronic digestive tract diseases with anxiety and depression states | |
| CN1051237C (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN1660395A (en) | Formula of treating apoplexy | |
| CN103394002B (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN103041081B (en) | Medicament composition for treating spleen-insufficiency diarrhea type irritable bowel syndrome and preparation method thereof | |
| CN105832991A (en) | Traditional Chinese medicine composition for treating gastritis | |
| CN101036723A (en) | Effective Chinese traditional medicine having a function of invigorating kidney and strengthening resistance and solidifying health | |
| CN1824204A (en) | Medicinal composition for treating acute urarthritis and its preparation method | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN1579485B (en) | Traditional Chinese medicinal composition for treating intestinal function disorder and its preparation method | |
| CN1063649C (en) | Red ginseng and hawthorn fruit health-care wine | |
| CN1111054C (en) | Medicine for treating apoplexy and its preparing process | |
| CN1240418C (en) | Chinese compound medicine for treating gastrodynia and its prepartion method | |
| CN1242791C (en) | Medicinal mixture and its preparation method | |
| CN1772053A (en) | Medicine composition for treating diarrhea type irritable bowel syndrome and its prepn | |
| CN1282475C (en) | Combination of medication for treating gallbladder disease and preparation method | |
| CN1333044A (en) | Wasting-thirst hypoglycemic preparation | |
| CN1301125C (en) | Medicine for treating gastrointestinal tract disease | |
| CN100342879C (en) | Liver fibrosis treating prepn and its process | |
| CN1049596C (en) | Medicine composite for curing arthritis | |
| CN1872165A (en) | A medicine combination, preparation method and method for controlling quality | |
| CN1449771A (en) | Repellent mixture for department of gynecology | |
| CN1958061A (en) | Technique for preparing Chinese traditional medicine and pills in use for clearing away heart-fire, dispersing phlegm, tranquilizing the mind, and reducing pressure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060412 Termination date: 20130128 |